Topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumor resection. There are currently no U.S. FDA approved adjuvant treatment options in this population of approximately 50,000 patients. Together with the Company’s data in high-risk BCG-unresponsive NMIBC, the PIVOT-006 results have the potential to significantly broaden the patient populations that could benefit from cretostimogene if approved.
PIVOT-006 achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus the control arm. Cretostimogene resulted in a 68% reduction in the risk of recurrence compared with the control arm, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001). The median follow-up was 17 months as of October 26, 2026. Cretostimogene was generally well tolerated, with safety results consistent with those reported in previous studies. There were no Grade 3 or greater treatment-related adverse events (TRAEs), and no treatment-related discontinuations.
"The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase 3 trial in intermediate-risk and HG Ta NMIBC. We are working expeditiously to complete our BLA filing in intermediate-risk and HG Ta NMIBC in the second quarter of 2027," said Arthur Kuan, Chairman, President and Chief Executive Officer of CG Oncology. "Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease. Together, these populations represent the full range of BCG-unresponsive patients, and our goal is a label that reflects that. To incorporate the additional data, we now expect to complete the submission before the end of March 2027. All BLA-enabling manufacturing activities supporting both regulatory filings have been completed. Ultimately, this strategy reflects our commitment to meaningfully improve the lives of as many bladder cancer patients as possible."
"Today’s results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum and build upon our robust body of clinical evidence including what we believe to be the best-in-disease safety and tolerability data reported," said Vijay Kasturi, M.D., Chief Medical Officer of CG Oncology. "For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden. The significant improvement in recurrence-free survival observed in PIVOT-006 across both high-grade and low-grade patients underscores the promise of cretostimogene as an important potential new treatment option following tumor resection. These data give us the opportunity to change clinical practice and help more people remain cancer-free longer while reducing the burden of their disease."